SCHEMBL12562128

SCHEMBL12562128

CN(C)CCOc1cc(-c2ccnc(N)n2)c(F)cc1NC(=O)C1COc2ccc(F)cc2C1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 18/20 0.66
ROCK1 Q13464 9/20 0.66
CDC42BPA Q5VT25 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1987854 0.94 ROCK2 (0.65) ROCK2ROCK1CDC42BPA
SCHEMBL12603127 0.94 ROCK2 (0.64) ROCK2ROCK1CDC42BPA
SCHEMBL1989256 0.92 ROCK2 (0.65) ROCK2ROCK1CDC42BPA
SCHEMBL1990273 0.92 ROCK2 (0.63) ROCK2ROCK1CDC42BPA
SCHEMBL1989434 0.90 ROCK2 (0.77) ROCK2ROCK1CDC42BPA
SCHEMBL12562192 0.85 ROCK2 (0.54) ROCK2ROCK1CDC42BPA
SCHEMBL12562188 0.84 ROCK2 (0.54) ROCK2ROCK1CDC42BPA
SCHEMBL12562191 0.84 ROCK2 (0.54) ROCK2ROCK1CDC42BPA
SCHEMBL12562061 0.83 ROCK2 (0.77) ROCK2ROCK1CDC42BPA
SCHEMBL1987914 0.82 CDC42BPA (0.83) ROCK2ROCK1CDC42BPA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-23 US disclosed
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-23 US disclosed
WO-2009079008-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS FENG YANGBO (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS ROCK1, RHOA, RHOT2 ROCK2 4/4885ROCK1 1/4885CDC42BPA 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.